Effects of probiotic yogurt on relative respiratory tract infections, urine, saliva biomarkers, and fecal bacterial load in Ugandan children: a randomized controlled trial
Abstract
This study evaluated the effects of locally produced probiotic yogurt on infectious diseases in Ugandan children aged 3–6 years. Over nine weeks, 196 children participated in a randomized, double-blind, placebo-controlled trial, consuming 125 ml daily of either probiotic yogurt containing Lacticaseibacillus rhamnosus yoba 2012 and Streptococcus thermophilus C106 or a non-fermented dairy placebo. The primary outcome, average daily incidence of upper respiratory tract symptoms, showed no significant difference between groups. However, the probiotic yogurt group experienced a significant reduction in respiratory tract infection symptoms over time (p = 0.02). Biomarker analysis revealed significant changes in the probiotic yogurt group, including higher urine hippurate levels (p = 0.02), increased lactic acid bacteria (p = 0.04) and total bacterial load (p = 0.04) in stool, and elevated SLPI (p = 0.005) in saliva from baseline to endline. Despite these within-group effects, the lack of significant differences between the yogurt and placebo groups highlights the need for further research with larger cohorts and longer durations to confirm the potential benefits of this probiotic yogurt for reducing infection symptoms and improving health biomarkers under these study conditions.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 196 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.